Skip NavigationSkip to Content
Return Return to Search Results

Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib

  1. Author:
    Sun, K.
    Welniak, L. A.
    Panoskaltsis-Mortari, A.
    O'Shaughnessy, M. J.
    Liu, H. Y.
    Barao, I.
    Riordan, W.
    Sitcheran, R.
    Wysocki, C.
    Serody, J. S.
    Blazar, B. R.
    Sayers, T. J.
    Murphy, W. J.

  2. Author Address

    Murphy, WJ, Univ Nevada, Dept Microbiol & Immunol MS320, Reno, NV 89557 USA Univ Nevada, Dept Microbiol & Immunol MS320, Reno, NV 89557 USA. Univ Minnesota, Ctr Canc, Minneapolis, MN 55455 USA. Univ Minnesota, Dept Pediat, Div Bone Marrow Transplantat, Minneapolis, MN 55455 USA. Millennium Pharmaceut, Cambridge, MA 02139 USA. Univ N Carolina, Sch Med, Lineberger Canc Ctr, Chapel Hill, NC 27599 USA. NCI, Basic Sci Program, SAIC Frederick, Expt Immunol Lab,Ctr Canc Res, Frederick, MD 21702 USA.
    1. Year: 2004
  2. Journal: Proceedings of the National Academy of Sciences of the United States of America
    1. 101
    2. 21
    3. Pages: 8120-8125
  4. Type of Article: Article
  1. Abstract:

    Graft-versus-host disease (GVHD) represents a major hurdle impeding the efficacy of allogeneic bone marrow transplantation (BMT). Bortezomib is a proteasome inhibitor that was recently approved for treatment of myeloma. We found that bortezomib potently inhibited in vitro mixed lymphocyte responses and promoted the apoptosis of alloreactive T cells. Bortezomib given at the time of allogeneic BMT in mice resulted in significant protection from acute GVHD. Reductions in GVHD-associated parameters and biological evidence of proteasome inhibition were observed with this regimen but with no adverse effects on long-term donor reconstitution. Assessment of graft-versus-tumor responses in advanced leukemia-bearing mice demonstrated that only the combination of allogeneic BMT and T cells with bortezomib promoted significant increases in survival. increased cytotoxic T cell killing of the tumor was also observed. Thus, the combination of proteasome inhibition with selective immune attack can markedly increase the efficacy of BMT in cancer

    See More

  1. Keywords:

External Sources

  1. No sources found.

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel